Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet

Physiological Research

Volumn 58, Issue 2, 2009, Pages 203-209

  Sena, C M ^a,b   Louro, T ^a,b   Matafome, P ^a,b   Nunes, E ^a,b   Monteiro, P ^c   Seica R ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Coimbra University Hospital and Medical School ^*

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Diabetes mellitus; Endothelium; Gliclazide; Nitric oxide; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8-HYDROXY-2'-DEOXYGUANOSINE; ACETYLCHOLINE; ANTIDIABETIC AGENT; ANTIOXIDANT; DEOXYGUANOSINE; DRUG DERIVATIVE; GLICLAZIDE; NITRIC OXIDE; VASODILATOR AGENT;

ANIMAL; ARTICLE; BODY WEIGHT; DIABETIC ANGIOPATHY; DISEASE MODEL; DRUG EFFECT; DYSLIPIDEMIA; FAT INTAKE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RAT; RAT STRAIN; URINE; VASODILATATION; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; ANTIOXIDANTS; BODY WEIGHT; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIETARY FATS; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; GLICLAZIDE; HYPOGLYCEMIC AGENTS; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, MUTANT STRAINS; RATS, WISTAR; VASODILATION; VASODILATOR AGENTS;

EID: 66349113765     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.931480     Document Type: Article

References (27)

1. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
2. Campbell DB, Lavielle R, Nathan C: The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract 14 (Suppl 2): S21-S36, 1991.
3. Ceriello A, Quatraro A, Giugliano D: Diabetes mellitus and hypertension: the possible role of hyperglycaemia through oxidative stress. Diabetologia 36: 265-266, 1993.
4. Chang KC, Chung SY, Chong WS, Suh JS, Kim SH, Noh HW, Seong BW, Ko HJ, Chun KW: Possible superoxide radical-induced alteration of vascular reactivity in aortas from streptozotocin- treated rats. J Pharmacol Exp Ther 266: 992-1000, 1993.
5. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, Muller D, Park JK, Luft FC, Mervaala EM: Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 37: 433-439, 2001.
6. Da Ros R, Assaloni R, Ceriello A: Antioxidant therapy in diabetic complications: what is new? Curr Vasc Pharmacol 2: 335-341, 2004
7. Desfaits AC, Serri O, Renier G: Gliclazide decreases cell mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metabolism 46: 1150-1156, 1997.
8. Diederich D, Skopec J, Diederich A, Dai FX: Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 266: H1153-H1161, 1994.
9. Durante W, Sen AK, Sunahara FA: Impairment of endothelium- dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol 94: 463-468, 1988.
10. Fortes ZB, Leme JG, Scivoletto R: Vascular reactivity in diabetes mellitus: role of the endothelial cells. Br J Pharmacol 79: 771-781, 1983.
11. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996.
12. Hamilton SJ, Chew GT, Watts GF: Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diabetes Vasc Dis Res 4: 89-102, 2007.
13. Jennings PE, Scott NA, Saniabadi AR, Belch JJF: Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessments. Metabolism 41: 36-39, 1992.
14. Nichols CG, Lederer WJ: Adenosine triphosphate sensitive potassium channels in the cardiovascular system. Am J Physiol 261: H1675-H1686, 1992.
15. O'Brien RC, Luo M: The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism 46: 22-25, 1997.
16. O'Brien RC, Luo M, Balazs N, Mercuri J: In vitro and in vivo antioxidant properties of gliclazide. J DiabetesComplications 14: 201-206, 2000.
17. Pagano PJ, Griswold MC, Ravel D, Cohen RA: Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits. Diabetologia 41: 9-15, 1998.
18. Palmer KJ, Brogden RN: Gliclazide. An update of its pharmacological properties and therapeutic efficacy in noninsulin dependent diabetes mellitus. Drugs 46: 92-125, 1993.
19. Pennathur S, Heinecke JW: Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci 9: 565-574, 2004.
20. Rodríguez-Mañas L, Angulo J, Peiró C, Llergo JL, Sánchez-Ferrer P, López-Dóriga P, Sánchez-Ferrer CF: Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. Br J Pharmacol 123: 1495-1502, 1998.
21. Scott NA, Jennings PE, Brown J, Belch JJF: Gliclazide: a free radical scavenger. Eur J Pharmacol 208: 175-177, 1991.
22. Seiça RM, Suzuki KI, Santos RM, Rosário LM: Impaired insulin secretion in isolated islets of Goto-Kakizaki rats, an animal model of non obese type 2 diabetes, is a primary event. (in Portuguese) Acta Med Port 17: 42-48, 2004.
23. Sena CM, Barosa C, Nunes E, Seica R, Jones JG: Sources of endogenous glucose production in the Goto-Kakizaki diabetic rat. Diabetes Metab 33: 296-302, 2007.
24. Sena CM, Nunes E, Louro T, Proença T, Fernandes R, Boarder MR, Seiça RM: Effects of alphalipoic acid on endothelial function in aged diabetic and high-fat fed rats. Br J Pharmacol 153: 894-906, 2008.
25. Vallejo S, Angulo J, Peiró C, Navado J, Sánchez-Ferrer A, Petidier R, Sánchez-Ferrer CF, Rodríguez-Mañas L: Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia 43: 83-90, 2000b.
26. Vallejo S, Angulo J, Peiró C, Sánchez-Ferrer A, Cercas E, Llergo JL, Nevado J, Sánchezferrer CF, Rodríguez-Mañas L: Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment. J Diabetes Complications 14: 224-233, 2000a.
27. Young IS, Tate S, Lightbody JH, Mcmaster D, Trimble ER: The effects of desferoxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat. Free Radical Biol Med 18: 833-840, 1995.